Has the CSL share price got further to fall?

ASX experts weigh in on what's next for CSL.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Well, things were looking up for the CSL Ltd (ASX: CSL) share price. Until 12 February earlier this month, that is. 

Between late October and 12 February, CSL shares were on a tear. This ASX 200 healthcare stock rose more than 32% between those two dates. But after the company released some bitterly disappointing test results for a new cardiovascular drug, investors lost a lot of their confidence.

Since 12 February, CSL shares have tanked by more than 6.6%, falling from over $300 each to the $285.50 we see today (at market close).

Not even a confident earnings report earlier this month could restore investor enthusiasm. As we covered at the time, those earnings revealed that CSL was able to record an 11% rise in revenues, as well as a 20% increase in net profits for the six months ending 31 December. Investors were also treated to a 12% dividend pay rise.

Check out the CSL share price's movements below for yourself:

So with CSL shares coming off the boil and seemingly not getting back on, ASX investors might be asking themselves whether CSL shares have further to fall. After all, it was only in late October that this healthcare giant got as low as $228.65 a share.

Research, collaboration and doctors working digital tablet, analysis and discussion of innovation cancer treatment. Healthcare, teamwork and planning by experts sharing idea and strategy for surgery.

Image source: Getty Images

Does the CSL share price have further to fall?

Well, let's see what some ASX experts think.

Following the release of CSL's earnings, my Fool colleague James covered the views of ASX broker Morgans. Morgans did trim its price target for CSL shares following its disappointing trial results. But it still rates the company as an add following its earnings, with a price target of $315.40. If realised, that would represent an upside of more than 10% from current prices.

Morgans was happy with what CSL reported earlier this month and evidently sees significant value in the company's share price at its current levels.

But Morgans isn't the only expert that is eyeing off the healthcare giant right now. eToro analyst Josh Gilbert shares a positive view. Here's some of what he recently said about CSL right now:

CSL shareholders will have reason to smile today with the release of a solid half-yearly report… [These] results show that the business continues to move in the right direction, and there is plenty to be positive about. With solid profit growth, a healthy dividend, solid guidance, and interest rate cuts not far away, CSL will be on investors' watchlists.

So it appears that at least two ASX experts reckon CSL shares are more likely to head up than down going forward. But, as always, we'll have to wait and see if that turns out to be the case.

Motley Fool contributor Sebastian Bowen has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

This ASX healthcare rocket is up 14% in a week. Here's why investors are still buying

A new acquisition has put this ASX healthcare stock back in focus today.

Read more »

Three health professionals at a hospital smile for the camera.
Healthcare Shares

Pro Medicus renews $28m contract with Allegheny Health Network

Pro Medicus renewed a $28 million contract with Allegheny Health Network, expanding its Visage 7 workflow for ongoing growth.

Read more »

An older woman tries to listen by cupping her ear.
Healthcare Shares

What happened to Cochlear shares in May?

Cochlear shares crashed 62% in 2026 after a massive earnings downgrade. Here's what happened in May and what comes next.

Read more »

A woman with bright yellow hair wearing a brightly patterned blouse reacts to big news that she's reading on her phone.
Healthcare Shares

Historic: Here's why CSL shares are looking very interesting right now

CSL's yield now rivals a big four bank...

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

4DMedical shares jump 11% as investors cheer major US agreement

4DMedical has landed another commercial foothold in the US.

Read more »

A man and woman sit next to each other looking at each other and feeling excited and surprised after reading good news about their shares on a laptop.
Healthcare Shares

Which ASX healthcare stock could rise over 100% according to Bell Potter?

Let's see what the broker is saying about this stock this week.

Read more »

Research, collaboration and doctors working digital tablet, analysis and discussion of innovation cancer treatment. Healthcare, teamwork and planning by experts sharing idea and strategy for surgery.
Healthcare Shares

These 3 ASX healthcare stocks have been crushed in 2026. They could be set for a comeback

CSL is at a 10-year low. Cochlear has fallen 62%. ResMed is down on fears that proved wrong. Are any…

Read more »

A male doctor wearing a white lab coat shrugs his shoulders and holds his hands up in the air looking confused
Healthcare Shares

Should I buy CSL shares in June?

Here's what I expect from the beaten-down biotech stock next month.

Read more »